Antioxidant supply — second-source qualification

From Filings · Engaged

5 agents · last run 01:22 todayDraft outreach

$200Kestimated value

0/5roles covered

11sources behind the signal

Engagedstage

Lowrelevance · ranked 22 of 23

Overview Signals3 People0 Win Kit

Why this exists

This puts a competitor-held position in play for the first time in four years.

The chain

what produced this, and what it still needs

1 · Signal

Arkema and Solvay have formed an alliance that changes the qualification path

Market Moves · 4 sources Medium confidence

Open signal →

2 · Opportunity

Scored 22 of 23 surfaced · $200K

Above the relevance bar 137 scored, 23 surfaced

you are here

3 · People

0 of 5 roles mapped

Missing: Funds itFind who funds it →

4 · Draft

Not started

Win Kit is ready — 3 proof points and a competitive counter.

Draft outreach →

Win Kit

in your licence

Value hypothesis

Qualification time is the binding constraint, not price.

Proof points

01Qualified at an adjacent site in 11 weeks
02Meets the 2027 restriction threshold today
03Existing MSA removes commercial negotiation from the path

Competitive counter

Incumbent is Solvay; their grade does not clear the new limit.

Commercial angle

Lead with a paid trial to compress the qualification decision.

Buying group

0 of 5 roles covered

Funds it

Nobody mapped · BU leader

Map the group →

Qualifies it

Nobody mapped · R&D

Map the group →

Buys it

Nobody mapped · Procurement

Map the group →

Approves it

Nobody mapped · EHS / Regulatory

Map the group →

Runs it

Nobody mapped · Plant Ops

Map the group →